In the most recent trading session, Amgen (AMGN) closed at $267.10, indicating a -1.14% shift from the previous trading day.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

A $5,000 investment can go a long way, especially if you're loading up on fairly cheap stocks that may possess a lot of upside in the long run. By investing $5,000, you can ensure that if you pick a g...

Amgen Inc. (NASDAQ:AMGN ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 6:00 PM ET Company Participants Robert Bradway - Chairman, CEO & President Conference Call Participants Ch...

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, stocks that pay dividends regularly can be great additions to your portfolio.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinica...

Amgen (AMGN) closed at $262.05 in the latest trading session, marking a +1.34% move from the prior day.

Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Since my previous article, shares of Amgen meaningfully lagged the S&P 500 index. The company's revenue and non-GAAP EPS climbed higher in the third quarter. Amgen's deleveraging efforts are progressi...

CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to IMDYLLTRA® for...

Amgen's strong product portfolio and pipeline developments, including, but not limited to, IMDELLTRA and MariTide, support a "Strong Buy" rating for long-term investors despite upcoming patent expirat...

The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.

No one knows for sure what the new year will hold for the market. However, some stocks' chances for success look particularly good.

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Dow Jones Industrial Average contains 30 handpicked companies that are, or at least once were, leaders in their respective industries. This makes the index an interesting hunting ground for high-y...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...